SCHEMBL3673673

SCHEMBL3673673

[N-]=[N+]=CC(=O)c1cccc2c1OCCO2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
CTNNB1 P35222 3/20 0.46
WNT3A P56704 3/20 0.46
MTNR1A P48039 8/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
MRGPRX1 Q96LB2 1/20 0.38
PTGER3 P43115 1/20 0.37
HTR4 Q13639 1/20 0.37
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5214590 0.77 CTNNB1 (0.55) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL30220126 0.75 KDM4E (0.56) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL251991 0.75 KDM4E (0.56) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL637323 0.74 CTNNB1 (0.55) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL1020885 0.74 CTNNB1 (0.52) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL1520075 0.74 PARP1 (0.64) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL5215083 0.71 MAPT (0.57) KDM4ECTNNB1WNT3A
SCHEMBL639330 0.70 CTNNB1 (0.59) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL15844494 0.70 CTNNB1 (0.52) KDM4ECTNNB1WNT3AMTNR1AHDAC3
SCHEMBL2895789 0.70 CTNNB1 (0.58) KDM4ECTNNB1WNT3AMTNR1AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R KDM4E 2651/4885CTNNB1 4101/4885WNT3A 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.